{
    "root": "f76dd82b-2525-464c-b58c-048c3475977f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "AMOXICILLIN AND CLAVULANATE POTASSIUM",
    "value": "20241216",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "ETHYLCELLULOSE (10 MPA.S)",
            "code": "3DYK7UYZ62"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "AMOXICILLIN",
            "code": "804826J2HU"
        },
        {
            "name": "CLAVULANATE POTASSIUM",
            "code": "Q42OMW3AT8"
        }
    ],
    "indications": "amoxicillin clavulanate potassium tablets indicated treatment infections adults pediatric patients , due susceptible isolates designated bacteria conditions listed : • lower respiratory tract infections- caused beta‑lactamase‑producing isolates haemophilus influenzaeand moraxella catarrhalis . • acute bacterial otitis media- caused beta‑lactamase‑producing isolates h. influenzaeand m. catarrhalis . • sinusitis- caused beta‑lactamase‑producing isolates h. influenzaeand m. catarrhalis . • skin skin structure infections- caused beta‑lactamase‑producing isolates staphylococcus aureus , escherichia coli , klebsiellaspecies . • urinary tract infections- caused beta‑lactamase‑producing isolates e. coli , klebsiellaspecies , enterobacterspecies . limitations susceptibility test results show susceptibility amoxicillin , indicating beta-lactamase production , amoxicillin clavulanate potassium tablets used . usage reduce development drug‑resistant bacteria maintain effectiveness amoxicillin clavulanate potassium tablets antibacterial drugs , amoxicillin clavulanate potassium tablets used treat prevent infections proven strongly suspected caused susceptible bacteria . culture susceptibility information available , considered selecting modifying antibacterial therapy . absence data , local epidemiology susceptibility patterns may contribute empiric selection therapy .",
    "contraindications": "adults pediatric patients greater 40 kg : 500 875 mg every 12 hours 250 500 mg every 8 hours , based amoxicillin component . ( 2.2 , 2.3 ) pediatric patients aged 12 weeks ( 3 months ) older : 25 45 mg/kg/day every 12 hours 20 40 mg/kg/day every 8 hours , adult dose . ( 2.3 ) neonates infants less 12 weeks age : 30 mg/kg/day divided every 12 hours , based amoxicillin component . 125 mg/5 ml oral suspension recommended . ( 2.3 )",
    "warningsAndPrecautions": "amoxicillin clavulanate potassium tablets , usp : 875 mg/125 mg tablets : white off-white colored , capsule shaped , biconvex , film-coated tablets debossed “ 07 ” one side score line side . tablet contains 875 mg amoxicillin trihydrate 125 mg clavulanic acid potassium salt ( equivalent 149 mg clavulanate potassium ) . ndc : 72162-2434-1 : 100 tablets bottle store 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] . dispense original container . advise patients keep closed container . keep reach children . repackaged/relabeled : bryant ranch prepack , inc.burbank , ca 9150",
    "adverseReactions": "history serious hypersensitivity reaction ( e.g . , anaphylaxis stevens-johnson syndrome ) amoxicillin clavulanate potassium beta‑lactams ( e.g . , penicillins cephalosporins ) . ( 4.1 ) history cholestatic jaundice/hepatic dysfunction associated amoxicillin clavulanate potassium . ( 4.2 )",
    "indications_original": "Amoxicillin and clavulanate potassium tablets are indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below:\n                  •\n \n  Lower Respiratory Tract Infections- caused by beta‑lactamase‑producing isolates of\n \n  Haemophilus influenzaeand\n \n  Moraxella catarrhalis. \n    •\n \n  Acute Bacterial Otitis Media- caused by beta‑lactamase‑producing isolates of\n \n  H. influenzaeand\n \n  M. catarrhalis. \n    •\n \n  Sinusitis- caused by beta‑lactamase‑producing isolates of\n \n  H. influenzaeand\n \n  M. catarrhalis. \n    •\n \n  Skin and Skin Structure Infections- caused by beta‑lactamase‑producing isolates of\n \n  Staphylococcus aureus, Escherichia coli,and\n \n  Klebsiellaspecies. \n    •\n \n  Urinary Tract Infections- caused by beta‑lactamase‑producing isolates of\n \n  E. coli, Klebsiellaspecies,\n \n  and\n \n  Enterobacterspecies. \n  \n                     Limitations of Use\n                       When susceptibility test results show susceptibility to amoxicillin, indicating no beta-lactamase production, amoxicillin and clavulanate potassium tablets should not be used. \n  \n                     Usage\n                       To reduce the development of drug‑resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium tablets and other antibacterial drugs, amoxicillin and clavulanate potassium tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",
    "contraindications_original": "Adults and Pediatric Patients greater than 40 kg: 500 or 875 mg every 12 hours or 250 or 500 mg every 8 hours, based on amoxicillin component. ( 2.2 , 2.3 ) Pediatric patients aged 12 weeks (3 months) and older: 25 to 45 mg/kg/day every 12 hours or 20 to 40 mg/kg/day every 8 hours, up to the adult dose. ( 2.3 ) Neonates and infants less than 12 weeks of age: 30 mg/kg/day divided every 12 hours, based on the amoxicillin component. Use of the 125 mg/5 mL oral suspension is recommended. ( 2.3 )",
    "warningsAndPrecautions_original": "Amoxicillin and Clavulanate Potassium Tablets, USP:\n                  875 mg/125 mg Tablets: White to off-white colored, capsule shaped, biconvex, film-coated tablets debossed with “I 07” on one side and score line on the other side. Each tablet contains 875 mg of amoxicillin as the trihydrate and 125 mg of clavulanic acid as the potassium salt (equivalent to 149 mg of clavulanate potassium).\n                  NDC: 72162-2434-1: 100 Tablets in a BOTTLE\n                  Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Dispense in original container. Advise patients to keep in closed container.\n                  Keep out of the reach of children.\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 9150",
    "adverseReactions_original": "History of a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin and clavulanate potassium or to other beta‑lactams (e.g., penicillins or cephalosporins). ( 4.1 ) History of cholestatic jaundice/hepatic dysfunction associated with amoxicillin and clavulanate potassium. ( 4.2 )"
}